fbpx
Size of letters 1x
Site color
Image
Additionally
Line height
Letter spacing
Font
Embedded items (videos, maps, etc.)
 

Ukrainian Clinical Trial Sites maintain Continuous Operations in CTs  and confirm their strong interest in New Clinical Trials

02/ 08/ 2023
  The EBA Clinical Trials Subcommittee has analyzed the status and level of adaptation of Ukrainian clinical trial sites after a year of the rfs full-scale war against Ukraine by conducting a survey among CT sites working with EBA CTS member companies.  The respondents are scattered throughout Ukraine, except for the temporarily occupied territories. The biggest share of CT sites that took part in the survey is located in the capital of Ukraine, Kyiv. These are 60 centers or 26%. Kharkiv is a close second, with 26 CT sites (13%) answering the survey. The third and fourth positions in terms of the number of respondents are occupied by Lviv (21 sites) and Ivano-Frankivsk (18 sites) regions. We also received 15 responses each from Zaporizhzhia and Dnipro. All other sites are almost evenly distributed across the countrys regions. A total of 227 centers participated in the survey.  In addition to the vast geography of the centers’ location, the therapeutic areas of CTs conducted at the centers are also diverse.  Most clinical trials are/were being conducted by respondents in the following areas: Cardiology (13%), Rheumatology (13%), Gastroenterology (12%), Pulmonology (11%), Endocrinology (10%). 9% of sites have\had trials in neurology and 7% - in oncology. 5% of trials at the sites are in the areas of Сovid-19, dermatology and other. The least covered therapeutic areas are hematology (4%), infectious diseases (3%), pediatrics and psychiatry (1% each).  93% (210 out of 227) of respondents say they have active clinical trials. Almost 100% of responding CT sites have adapted to work in current circumstances and now they are interested in new CTs, ready for them, fully operational and able to ensure continuous operations in CTs considering current circumstances. 216 CT sites out of 227 (95%) assess study drug supply in active CTs as adequate. Only 1 site considers the study drug supply as non-adequate, and 10 CT sites see some deficiencies.   89% of responders (203 CT sites) report about adequate level of the logistical support for the export of biosamples in active CTs. Just 10% of them say they have some deficiencies.  Regarding the workload at the sites: 182 responders (80%) answer it is regular and 42 (19%) respondents report a low level of workload. In addition to this, 98% of centers (223) follow their regular working schedule.  96% of respondents (218 CT sites) have a sufficient CT team. Also, 96% of the survey participants do not experience any operational difficulties with Local Ethic Commission or Competent Authority and 94% say there are no restrictions for monitors to visit their CT site.  93% of surveyed sites assess their patients pool as the same or increased. 64 % of Ukrainian CT sites have active feasibilities and 37 % even have active CTs in start-up.  Thus, the results of the survey demonstrate adaptation of СT sites and CT infrastructure to current circumstances, and their readiness to be involved in new CTs.   The survey was conducted by Clinical Trials Subcommittee of the European Business Association from May 5 – 31, 2023 among clinical trial sites working with EBA CTS member companies; 227 answers received. Also the results can be seen via the link

The EBA Clinical Trials Subcommittee has analyzed the status and level of adaptation of Ukrainian clinical trial sites after a year of the rf’s full-scale war against Ukraine by conducting a survey among CT sites working with EBA CTS member companies. 

The respondents are scattered throughout Ukraine, except for the temporarily occupied territories. The biggest share of CT sites that took part in the survey is located in the capital of Ukraine, Kyiv. These are 60 centers or 26%. Kharkiv is a close second, with 26 CT sites (13%) answering the survey. The third and fourth positions in terms of the number of respondents are occupied by Lviv (21 sites) and Ivano-Frankivsk (18 sites) regions. We also received 15 responses each from Zaporizhzhia and Dnipro. All other sites are almost evenly distributed across the country’s regions. A total of 227 centers participated in the survey. 

In addition to the vast geography of the centers’ location, the therapeutic areas of CTs conducted at the centers are also diverse.  Most clinical trials are/were being conducted by respondents in the following areas: Cardiology (13%), Rheumatology (13%), Gastroenterology (12%), Pulmonology (11%), Endocrinology (10%). 9% of sites have\had trials in neurology and 7% – in oncology. 5% of trials at the sites are in the areas of Сovid-19, dermatology and other. The least covered therapeutic areas are hematology (4%), infectious diseases (3%), pediatrics and psychiatry (1% each). 

93% (210 out of 227) of respondents say they have active clinical trials. Almost 100% of responding CT sites have adapted to work in current circumstances and now they are interested in new CTs, ready for them, fully operational and able to ensure continuous operations in CTs considering current circumstances.

216 CT sites out of 227 (95%) assess study drug supply in active CTs as adequate. Only 1 site considers the study drug supply as non-adequate, and 10 CT sites see some deficiencies.  

89% of responders (203 CT sites) report about adequate level of the logistical support for the export of biosamples in active CTs. Just 10% of them say they have some deficiencies. 

Regarding the workload at the sites: 182 responders (80%) answer it is regular and 42 (19%) respondents report a low level of workload. In addition to this, 98% of centers (223) follow their regular working schedule. 

96% of respondents (218 CT sites) have a sufficient CT team. Also, 96% of the survey participants do not experience any operational difficulties with Local Ethic Commission or Competent Authority and 94% say there are no restrictions for monitors to visit their CT site. 

93% of surveyed sites assess their patients pool as the same or increased. 64 % of Ukrainian CT sites have active feasibilities and 37 % even have active CTs in start-up. 

Thus, the results of the survey demonstrate adaptation of СT sites and CT infrastructure to current circumstances, and their readiness to be involved in new CTs.  

The survey was conducted by Clinical Trials Subcommittee of the European Business Association from May 5 – 31, 2023 among clinical trial sites working with EBA CTS member companies; 227 answers received. Also the results can be seen via the link

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Start
in the Telegram bot
Read articles. Share in social networks

Spelling error report

The following text will be sent to our editors: